KEYTRUDA (Merck Sharp & Dohme (Australia) Pty Ltd)
Product name
KEYTRUDA
Date registered
Evaluation commenced
Decision date
Approval time
192 (255 working days)
Active ingredients
pembrolizumab
Registration type
EOI
Indication
KEYTRUDA® (pembrolizumab), in combination with platinum-containingchemotherapy as neoadjuvant treatment, and then continued as monotherapy as adjuvant treatment, is indicated for the treatment of patients with resectable Stage II, IIIA, or IIIB (T3-4N2) NSCLC